Answers are grounded in this paper and cite their sources.
Gene-Eden (by polyDNA) is a broad range, natural antiviral supplement that targets viruses during their latent or chronic phase. The development of GeneEden was inspired by Hanan Polansky’s discovery [1] of the Starved Gene phenomenon. According to Polansky, the promoter/enhancer of certain common viruses, such as Epstein Barr Virus (EBV), Cytomegalovirus (CMV), and Herpes Simplex Virus (HSV), competes during latency with the promoter/enhancer of certain cellular genes for the limiting transcription complex GABP•p300/cbp. Retinoblastoma (Rb) and BRCA1 are two cellular genes that bind this complex. Since GABP•p300/cbp transactivates these genes, and since both genes encode a cell cycle suppressor, the presence of a high copy number of a sequestering latent virus in the nucleus diminishes the expression of the Rb and BRCA1 genes, which leads to excessive cell replication and a tumor. The patient is a 61-year-old female with an inoperable pancreatic carcinoma in the head of the pancreas with vascular involvement. The patient was receiving chemotherapy treatment of gemcitabine (Gemzar) + oxaliplatin (Eloxatin) + erlotinib (Tarceva) for a period of two months. During that time, test results and medical observations were showing a general worsening in the patient condition. The pancreatic tumor increased by 64% and was progressing towards mesenteric root (the size of the tumor was measured by the use of unidimensional measurements and the sum of the longest diameters). Hepatic mass increased by 22% and new hypodense masses were observed. Lymph nods were enlarged and increased in number. Concentration of red blood cells, hemoglobin, hematocrit, lymphocytes, eosinophils and basophils decreased by 21%, 23%, 10%, 78% and 100%, respectively. As a result, the original treatment was discontinued and a new chemotherapy treatment of capecitabine (Xeloda) was initiated. A week later, the patient began a treatment with Gene-Eden in addition to the chemotherapy. After fi ve weeks, a CT revealed a decrease of 35% in the tumor size, and a decrease of 18% in the hepatic mass. Blood test showed an increase in the concentration of lymphocytes (1.72 103 cells/μl compared with 0.70 103 cells/μl), eosinophils (0.11 103 cells/μl compared with 0 cells/μl) and basophils (0.02 103 cells/μl compared with 0 cells/μl), the new numbers were in the normal range and at levels similar to those observed prior to the initiation of the fi rst chemotherapy treatment. In addition, the patient gained weight, felt a relief in pain, was able to get up from bed alone and to walk around and was fi lling better in general. The question is whether these remarkable results should be attributed to the new chemotherapy treatment with capecitabine alone, or whether the addition of Gene-Eden had a major role in producing the observed remission. According to latest studies, treatments with capecitabine alone or in combination with other chemotherapy agents achieved results that range between stable disease and mild or partial responses. There are only a few studies to demonstrate physical tumor shrinkage. One such study [2], which examined the effect of capecitabine on tumor size, reports that only three of the 42 patients (7%) treated with capecitabine for advanced or metastatic pancreatic cancer A ct a O nc ol D ow nl oa de d fr om in fo rm ah ea lth ca re .c om b y 77 .1 27 .4 5. 3 on 0 8/ 02 /1 3
No takes yet. Share an insight, caveat, or question.
Polansky et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: